Imara Announces Presentation at the Annual Sickle Cell and Thalassaemia Conference Company Provided Review of Ongoing Phase 2 Clinical Trial of IMR-687 October 24, 2018 12:00 PM Eastern Daylight Time ...

The data were presented during the Congress of Neurological Surgeons Meeting, September 28 – October 2, 2024, in Houston, TX. Early analysis of the results shows no dose-limiting toxicities or ...

BRISBANE, Calif., April 15, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that Sangamo scientists and collaborators will present data ...

Abstract Title: Development of a Sensitive and Robust Cell-Based Assay for Measuring Potency of the NAV AAV8 Vector-Derived RGX-314 Gene Therapy Product for the Treatment of Wet Age-Related ...

WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...

WATERTOWN, Mass., May 5, 2025 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat au Wednesday 4 June 2025 04:57 GMT عربي ...

– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters highlight the safety data, tolerability data, and antitumor ...

Fact check: Claim on electric car charging efficiency gets some math wrong. But the claim is wrong on several fronts. The image is an illustration, not a photo. It shows an animal cell, not a ...

Cell & Gene Therapy World Conference CGTWC 2025 10 September 2025 09:00 - 12 September 2025 17:00, Boston, United States ... The agenda will feature presentations on the latest research findings, ...

The image appeared during a presentation by Mike McCauliffe, head of Luminar’s semiconductor team. The full Luminar Day webcast on YouTube, which had nearly 750,000 views, was taken down and ...

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant ...